<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799316</url>
  </required_header>
  <id_info>
    <org_study_id>Rasha Abdelno</org_study_id>
    <nct_id>NCT02799316</nct_id>
  </id_info>
  <brief_title>Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test Before Immunosuppressive Therapies?</brief_title>
  <official_title>Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test for Hepatitis B Virus Infection in Rheumatic Disease Patients Before Starting Immunosuppressive Therapies??</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B virus (HBV) infection is a challenging health problem. According to the World
      Health Organization, an estimated 240 million individuals (3.7%) suffered from chronic HBV
      infection worldwide.

      After acute hepatitis B virus (HBV) infection, the disappearance of hepatitis B surface
      antigen (HBsAg) had generally been believed to signify viral elimination. However, it now
      becomes clear that those subjects may have occult HBV infection which is defined as the
      presence of HBV DNA in the liver in the absence of HBsAg in the serum. Occult HBV infection
      usually accompanies antibody against hepatitis B core antigen (anti-HBc) and/or antibody
      against HBsAg (anti-HBs), but some cases might not have these serological markers
      (seronegative occult HBV infection) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a recent systematic review, nearly 40% of HBsAg carriers and 5% of antiHBc-positive but
      HBsAg-negative patients developed HBVr during TNF inhibitor therapy.

      Considering the lifelong use of multiple antirheumatic drugs, we need more specific
      guidelines for the management of rheumatic disease patients who are scheduled to receive
      biological and/or non-biological DMARDs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with occult HBV.</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients having occult HBV.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>rheumatic disease with HBs-ag positive</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>• HBV core antibodies testing. • Real time PCR testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HBV core antibodies testing. • Real time PCR testing.</intervention_name>
    <description>HBV core antibodies testing in HBV surface antigen negative patients.
Real time PCR testing for those having positive HBc antibodies.</description>
    <arm_group_label>rheumatic disease with HBs-ag positive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Any patients with rheumatic disease with hepatitis B surface antigen negative.

        Exclusion Criteria:

          -  • Overt co-morbid condition.

               -  Any malignancy e.g. HCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasha A Abdel Noor, Consultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal medicine department - Tanta university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Gastroenterology and Hepatology- Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walaa Elkhalawany, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>liver diseases dept.-Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Watani, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>liver diseases dept.-Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rehab Badawi, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>liver diseases dept.-Tanta university hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, Consultant</last_name>
    <phone>00201095159522</phone>
    <email>sherif_tropical@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-elsalam, lecturer</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>June 17, 2017</last_update_submitted>
  <last_update_submitted_qc>June 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Consultant liver and GIT diseases- Tanta university hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

